Skip to content Skip to sidebar Skip to footer

GlaxoSmithKline (GSK)

Technologies | GSK

Approximately 70% of our targets in research are genetically validated The success of our R&D rests not just on finding new treatments, but on getting better at how we find them. The key to that is combining human genetics, genomics and advanced technologies to make better predictions about who a treatment might work for, and…

Read More

GSK announces expanded collaboration with Tempus in precision medicine to accelerate R&D

Collaboration leverages one of world’s largest sources of de-identified patient data to accelerate drug discovery, initially in oncology Access will enable GSK to improve clinical trial design, speed up enrolment and identify drug targets GSK plc (LSE/NYSE: GSK) and Tempus, a US-based precision medicine company, have entered into a three-year collaboration agreement that provides GSK…

Read More